Here's what we'll cover
Here's what we'll cover
What's Actually Happening With Compounded GLP-1s
If you've been using a compounded version of semaglutide or tirzepatide to manage your weight, you've probably heard some unsettling news lately. The FDA is tightening its rules around these medications, and many compounding pharmacies are being told they can no longer produce them at scale.
This isn't a sudden development. It's the result of a regulatory process that began when the FDA officially removed semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (found in Mounjaro) from its drug shortage list. Once a drug is no longer in shortage, the legal basis for large-scale compounding largely disappears.
The result is a significant shift for the millions of Americans who turned to compounded versions primarily because they were far more affordable than brand-name alternatives.
Why Compounded GLP-1s Became So Popular
To understand what's at stake, it helps to know why compounding existed in this space to begin with.
When Wegovy and Mounjaro were in short supply, the FDA allowed compounding pharmacies to produce their own versions of the active ingredients. This is a standard regulatory pathway for shortage situations. Compounded drugs are custom-prepared medications not commercially available in the needed form or dose.
The appeal was obvious. Brand-name GLP-1 medications can cost $900 to $1,300 or more per month without insurance. Compounded semaglutide or tirzepatide from a telehealth provider often ran $150 to $400 per month. For patients paying out of pocket, it was the difference between accessing treatment and going without.
Millions of people took that route. And many of them report meaningful weight loss and improved health outcomes. The problem, according to the FDA and medical experts, isn't that the concept is flawed. It's that the execution is inconsistent and largely unmonitored.
What Doctors Are Worried About
Physicians and researchers have raised several specific concerns about compounded GLP-1 medications. These aren't hypothetical worries. Some issues have already shown up in adverse event reports.
Inconsistent Dosing
Compounding pharmacies are not all equivalent. Without the standardized manufacturing processes that Novo Nordisk and Eli Lilly use for their brand-name products, the concentration and stability of a compounded product can vary between batches, or even between vials from the same batch.
For GLP-1 medications, dosing precision matters. Too little and the medication doesn't work as intended. Too much and the risk of serious side effects like severe nausea, vomiting, and pancreatitis increases.
Unapproved Additives
Some compounding pharmacies have added ingredients like vitamin B12, L-carnitine, or other compounds to their formulations. These additions have not been tested in combination with semaglutide or tirzepatide. The FDA has flagged specific instances where these additives raised safety concerns.
Salt vs. Base Form
The FDA specifically warned about pharmacies using semaglutide sodium or semaglutide acetate instead of the base form of semaglutide used in approved medications. These are chemically different. The clinical effects of these salt forms haven't been studied in the way the approved drug has been.
No Post-Market Surveillance
When something goes wrong with a brand-name drug, Novo Nordisk and Eli Lilly are required to track it, report it, and respond. Compounding pharmacies don't face the same mandatory reporting infrastructure. That makes it harder to spot emerging safety signals across a large population.
What the FDA's Crackdown Actually Means Legally
The FDA's enforcement actions here operate through a specific legal framework. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding is permitted under defined conditions. One key condition for bulk compounding is that the drug is on the FDA shortage list.
When semaglutide and tirzepatide were removed from that list, the legal window for most compounding closed. The FDA issued guidance stating that 503A pharmacies (traditional compounding pharmacies) were expected to stop making these drugs. 503B outsourcing facilities, which operate at a larger scale with more oversight, faced a slightly different and more extended compliance timeline.
This doesn't mean all compounding pharmacies immediately stopped. Enforcement takes time, and some operations have continued while the regulatory dust settles. But the direction is clear: the FDA intends to end large-scale compounding of these medications.
Patients who received compounded GLP-1s through telehealth platforms may find that those options disappear or become more restricted over the coming months.
The Cost Problem This Creates
Here's the uncomfortable reality. The FDA's action is medically defensible. But it creates a genuine access problem.
Most insurance plans still don't cover GLP-1 medications for weight loss, even though obesity is a recognized chronic disease. Medicare Part D coverage for weight management with GLP-1s has expanded, but coverage remains inconsistent across commercial insurers.
The gap between compounded and brand-name pricing is stark. For many patients, especially those without adequate insurance coverage, this isn't just a financial inconvenience. It could mean stopping treatment entirely.
Real Options for Patients Who Are Affected
If you've been using compounded semaglutide or tirzepatide, you have a few realistic paths forward. None of them are perfect, but they're worth knowing about.
Check Manufacturer Savings Programs
Novo Nordisk offers the Wegovy Savings Card, which can reduce monthly costs to around $0 to $99 for eligible commercially insured patients. Eli Lilly has a similar program for Zepbound. These programs don't help everyone, particularly those on Medicare or Medicaid, but they're worth checking immediately.
Talk to Your Provider About Insurance Appeals
Insurance denials for GLP-1 medications can sometimes be overturned, especially when a physician documents obesity-related comorbidities like type 2 diabetes, hypertension, or sleep apnea. A prior authorization appeal with strong clinical documentation succeeds more often than many patients expect.
Explore Zepbound Vials
Eli Lilly sells Zepbound in single-dose vials at a meaningfully lower price point than the autoinjector pen format. This option, available directly through LillyDirect, has made tirzepatide more accessible for some cash-pay patients.
Compare Telehealth Providers
Some telehealth platforms are already adapting their offerings to focus on brand-name prescriptions with savings program integration. Comparing providers carefully is worth the effort. Check out Best Providers for a current breakdown of what's available.
Look Into GLP-1 Coupons and Assistance Programs
Patient assistance programs from manufacturers, as well as third-party discount options, can sometimes close the gap. You can explore current offers at GLP-1 Coupons.
Questions to Ask Your Doctor Right Now
If you're currently using a compounded GLP-1 or are worried about your access, your next conversation with your provider should cover a few specific points.
- Is my current compounded medication from a pharmacy that meets USP sterile compounding standards?
- What form of semaglutide or tirzepatide is in my compound? Is it the base form or a salt form?
- Do any additives in my compounded formula have known interactions or safety data?
- Would I qualify for a manufacturer savings program if I switch to a brand-name medication?
- Is there documentation in my chart supporting an insurance appeal or prior authorization?
These aren't adversarial questions. They're practical ones that any responsible provider should welcome.
How to Evaluate Whether Your Current Source Is Safe
Not all compounding pharmacies are equal, and not all telehealth platforms source from the same quality operations. If you're still using a compounded product while you sort out your next steps, here's what to look for.
503B vs. 503A Status
503B outsourcing facilities are registered with the FDA and subject to more rigorous inspections and quality standards than traditional 503A pharmacies. If your pharmacy is a 503B facility, that's a meaningful baseline of quality assurance. Ask your telehealth provider directly which category their pharmacy partner falls into.
Certificate of Analysis
Reputable compounding pharmacies can provide a certificate of analysis (COA) for each batch of medication. This document shows third-party testing results for potency and sterility. If a pharmacy can't or won't provide one, that's a red flag.
No Unapproved Additives
Ask specifically whether your formulation contains anything beyond the active ingredient and standard pharmaceutical excipients. Avoid products marketed with added vitamins, peptides, or supplements unless your physician has specifically reviewed and approved those additions for your situation.
No waiting list. No insurance needed.
Frequently Asked Questions
Is compounded semaglutide still legal to buy?
The legal status depends on the type of pharmacy and how the drug is being compounded. Since the FDA removed semaglutide from the shortage list, large-scale compounding is no longer legally supported for most pharmacies. Some 503B outsourcing facilities had extended compliance timelines, but the FDA's direction is clear that this pathway is closing. Talk to your provider about your current situation.
Is compounded semaglutide as effective as Wegovy or Ozempic?
There is no large-scale clinical trial data comparing compounded semaglutide directly to brand-name products. When properly compounded to the correct concentration using the base form of semaglutide, the active ingredient is the same. However, variability in concentration, stability, and additives can affect how well it works and how safe it is.
Why did the FDA remove semaglutide and tirzepatide from the shortage list?
The FDA determines shortage status based on manufacturer supply data and market availability. Novo Nordisk and Eli Lilly both reported that supply had caught up with demand, which triggered the removal of their respective drugs from the shortage list. This change removed the primary legal justification for large-scale compounding.
Can I keep taking my compounded GLP-1 while I figure out my next steps?
You should consult your prescribing physician before making any changes. If your current supply is from a reputable 503B pharmacy using the correct base form of the drug without unapproved additives, the immediate risk may be lower. However, you should be actively working on a transition plan given the changing regulatory environment.
What is the cheapest FDA-approved GLP-1 option right now?
Zepbound (tirzepatide) single-dose vials available through LillyDirect are currently one of the more affordable brand-name options for cash-pay patients, with some doses available at significantly lower prices than the autoinjector format. Manufacturer savings cards for Wegovy and Zepbound can also reduce costs substantially for eligible commercially insured patients.
What are the actual risks of compounded GLP-1 medications?
Documented risks include receiving the wrong dose due to concentration errors, exposure to unapproved additives with unknown interactions, and use of salt forms of semaglutide that haven't been tested for safety or efficacy. The FDA received adverse event reports linked to compounded GLP-1 products, including hospitalizations, though causality in individual cases can be difficult to establish.
The Bottom Line for Patients
The FDA's crackdown on compounded GLP-1s puts many patients in a genuinely difficult position. The concerns driving this action are legitimate. Inconsistent dosing, unapproved additives, and unregulated manufacturing are real problems, not bureaucratic overreach. At the same time, the cost barrier to brand-name alternatives is real too, and it will force some people off treatment who were doing well.
If you're currently using a compounded GLP-1 medication, the single most important thing you can do right now is have an honest conversation with your prescribing provider. Don't stop your medication abruptly without guidance. Don't assume your current source is automatically unsafe. But do take stock of what you're using, where it comes from, and what your options are.
The path forward looks different for different people. Some will qualify for manufacturer savings programs that make brand-name drugs affordable. Some will win insurance appeals with the right clinical documentation. Some may face a genuine gap in access and need support navigating that. None of these situations are simple, and the answers depend on your specific health profile, insurance coverage, and financial circumstances.
What you don't have to do is figure this out alone.
GLP-1.com has up-to-date comparisons of telehealth providers who prescribe brand-name GLP-1 medications, along with information on savings programs and discount options. Start with the Best Providers page to see which platforms are currently offering supported access to FDA-approved GLP-1 treatments. And check GLP-1 Coupons for current manufacturer savings and patient assistance programs that may apply to your situation.
The regulatory landscape is shifting, but your access to effective obesity treatment doesn't have to shift with it.